Yatsen Holding Limited (YSG) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with increased gross margin, reduced operating losses, and a shift to non-GAAP net income. The strategic focus on high-margin skincare and R&D investments, alongside a share repurchase program, indicates confidence in future growth. Positive Q3 guidance for skincare and improved profitability strategies further bolster the outlook. Despite increased competition, the company's robust R&D capabilities and strategic initiatives suggest a positive trajectory. The Q&A section supports this with no significant concerns raised by analysts, reinforcing the positive sentiment.
Key Financial Performance
Total Net Revenues Increased by 36.8% year-over-year to RMB 1.09 billion from RMB 794.5 million. This increase was primarily due to a 78.7% year-over-year increase in net revenues from skincare brands, combined with an 8.8% year-over-year increase in net revenues from color cosmetics brands.
Gross Profit Increased by 39.5% year-over-year to RMB 850.4 million from RMB 609.4 million. The increase was primarily driven by an increase in sales of higher gross margin products.
Gross Margin Increased to 78.3% from 76.7% for the prior year period. The increase was primarily driven by an increase in sales of higher gross margin products.
Total Operating Expenses Increased by 21.7% year-over-year to RMB 905.9 million from RMB 744.6 million. As a percentage of total net revenues, total operating expenses decreased to 83.4% from 93.7% for the prior year period.
Fulfillment Expenses Increased to RMB 63.3 million from RMB 51.2 million. As a percentage of total net revenues, fulfillment expenses decreased to 5.8% from 6.4% for the prior year period. The decrease was primarily due to further improvement in logistics efficiency.
Selling and Marketing Expenses Increased to RMB 722.4 million from RMB 544.7 million. As a percentage of total net revenues, selling and marketing expenses decreased to 66.5% from 68.6% for the prior year period. The decrease was primarily driven by deleveraging effect of higher total net revenues.
General and Administrative Expenses Decreased to RMB 84.1 million from RMB 119.1 million. As a percentage of total net revenues, general and administrative expenses decreased to 7.7% from 15%. The decrease was primarily driven by lower payroll expenses resulting from a reduction in general and administrative headcount, coupled with deleveraging effect of higher total net revenues.
Research and Development Expenses Increased to RMB 36.1 million from RMB 29.7 million. As a percentage of total net revenues, research and development expenses decreased to 3.3% from 3.7%. The decrease was primarily driven by deleveraging effect of higher total net revenues.
Loss from Operations Decreased to RMB 55.5 million from RMB 135.2 million. Operating loss margin decreased to 5.1% from 17% for the prior year period.
Non-GAAP Loss from Operations Decreased to RMB 20.4 million from RMB 111.9 million. Non-GAAP operating loss margin decreased to 1.9% from 14.1% for the prior year period.
Net Loss Decreased to RMB 19.5 million from RMB 85.5 million. Net loss margin decreased to 1.8% from 10.8% for the prior year period.
Non-GAAP Net Income Increased to RMB 11.5 million from a non-GAAP net loss of RMB 74.9 million. Non-GAAP net income margin increased to 1.1% from a non-GAAP net loss margin of 9.4% for the prior year period.
Cash, Restricted Cash, and Short-term Investments As of June 30, 2025, amounted to RMB 1.35 billion compared to RMB 1.36 billion as of December 31, 2024.
Net Cash Generated from Operating Activities Increased to RMB 77.7 million from net cash used in operating activities of RMB 148.2 million for the prior year period.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue growth in skincare brands: Increased by 78.7% year-over-year, driven by 88.1% growth in Galénic, DR.WU, and Eve Lom.
New product launches: Galénic's upgraded Brightening Micro Mask ranked #1 among premium single-use masks on Tmall and JD. Perfect Diary introduced Biophased Essence Foundation and translucent blurring setting powder.
R&D-driven product innovation: Focused on biotech technology and emotional skincare, including participation in international conferences and unveiling innovations.
Expansion of offline presence: Galénic opened experience stores in Guangzhou, Shanghai, Wuhan, and Shenzhen to strengthen brand visibility.
International collaboration: Deepened partnerships with global R&D talent and institutions to enhance innovation.
Improved operational efficiency: Net loss margin reduced to 1.8% from 10.8% year-over-year. Non-GAAP net profit margin achieved at 1.1%.
Cost management: Selling and marketing expenses as a percentage of revenue decreased to 66.5% from 68.6%.
Focus on R&D and innovation: Strengthened R&D capabilities and presence in the scientific community, including joint laboratory initiatives and participation in global conferences.
Social responsibility initiatives: Launched programs like Create A Beautiful Life and DR.WU's campus charity tour to support low-income women and promote skincare education.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: China's beauty industry experienced modest growth, with beauty sales increasing by only 2.6% year-over-year, underperforming the 5.4% growth in total retail sales of consumer goods. This indicates a challenging market environment for the company.
Revenue Growth Sustainability: While the company achieved significant revenue growth of 36.8% year-over-year, the sustainability of this growth remains uncertain given the modest overall market growth and potential future economic uncertainties.
Operating Expenses: Total operating expenses increased by 21.7% year-over-year, which, although lower as a percentage of revenue compared to the prior year, still represents a significant cost burden that could impact profitability.
Regulatory Risks: The company operates in a highly regulated industry, and any changes in regulations or compliance requirements could adversely affect operations and financial performance.
Supply Chain and Logistics: Although fulfillment expenses decreased as a percentage of revenue, any disruptions in the supply chain or logistics could negatively impact the company's ability to deliver products efficiently.
Competitive Pressures: The beauty industry is highly competitive, and the company faces pressure to continuously innovate and maintain its market position, which could strain resources and impact margins.
Economic Uncertainties: Broader economic uncertainties, including consumer spending patterns and potential macroeconomic challenges, could adversely affect the company's performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: For the third quarter of 2025, the company expects total net revenues to be between RMB 778.6 million and RMB 880.1 million, representing a year-over-year increase of approximately 15% to 30%.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:As we enter into the second half of the year, how should we expect the trends of profitability for both skincare and color cosmetic categories? How do we intend to strike a balance between promoting new product lines and improving profitability?
A:The company aims to balance growth and profitability without sacrificing one for the other. High-end skincare brands, which have higher gross margins, are growing faster than color cosmetics. The company is confident in achieving both growth and profitability, especially as skincare shows stronger growth momentum.
Q:What is the company's view on industry competition in Q3 and Q4, particularly from foreign premium brands?
A:Competition is expected to intensify, especially as high-end skincare brands grow faster. To strengthen its competitive position, the company is adopting an R&D-driven growth strategy, heavily investing in R&D over the past 4-5 years. The company has built a world-class R&D team and infrastructure, including a top-tier R&D center in Shanghai.
Q:What are the key drivers behind the rapid growth of skincare brands, especially Galénic and DR.WU, in the first half of the year? What is the outlook for the skincare business in the second half and next year?
A:The growth is driven by continued R&D investment and systematic upgrades in R&D capabilities, resulting in a strong pipeline of new product innovations. Examples include new products like Galénic's VA serum and Micro Mask series, and DR.WU's Essence Toner. The company has provided Q3 guidance of 15%-30% growth, reflecting a positive outlook for skincare brands.
Q:In which areas will the company make efforts to continuously improve profitability?
A:The company plans to optimize its channel and product mix, streamline operating expenses, and invest in brand awareness and equity. Profitability improvement will be gradual. Additional efforts include driving premiumization, improving marketing efficiency through data-driven CRM, enhancing supply chain and operational efficiency, and gaining operating leverage as top-line growth continues.
Q:Review of Unclear Management Responses
A:No questions were identified where management avoided giving a direct answer or lacked clarity in their responses.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Beautiful Life
Biophased Essence
Brightening Micro
CEO Chairman
Capital Limited
Chairman Directors
China Cosmetic
China Women
China summary
Citic Securities
Co Ltd
Conference Shanghai
Conference Yunnan
Conference today
Congress Helsinki
Cosmetic Science
Cosmetics Conference
Council Nurse
Create Beautiful
DRWU campus
Foundation
Galénic
International
Research Division
brand product
effort
industry
makeup
portfolio
presence
product highlight
program
serum
skincare brand
store
summary result
technology
YSG Transcript
Yatsen Holding Limited (YSG) Q1 2026 Earnings Call Transcript
Neutral5-26
Yatsen Holding Limited (YSG) Q4 2025 Earnings Call Transcript
Unknown3-2
The company shows strong revenue growth and improved profitability, yet faces challenges with high marketing expenses and reliance on skincare. Despite an optimistic guidance, the Q&A reveals no new partnerships or groundbreaking strategies. With no market cap data, the impact is uncertain, but the mixed signals and existing risks suggest a neutral stock price movement.
Yatsen Holding Limited (YSG) Q3 2025 Earnings Call Transcript
Positive11-17
The earnings call highlights strong financial performance, with significant revenue and gross profit growth, improved margins, and reduced losses. The Q&A section reveals optimism about profitability in Q4 and sustained growth through R&D and marketing optimization. Despite competition, the company's strategy to focus on high-end brands and innovation is promising. The lack of detailed guidance on expenses is a minor concern, but overall, the positive financial results and optimistic outlook suggest a positive stock price movement.
Yatsen Holding Limited (YSG) Q2 2025 Earnings Call Transcript
Positive8-21
The earnings call reveals strong financial performance with increased gross margin, reduced operating losses, and a shift to non-GAAP net income. The strategic focus on high-margin skincare and R&D investments, alongside a share repurchase program, indicates confidence in future growth. Positive Q3 guidance for skincare and improved profitability strategies further bolster the outlook. Despite increased competition, the company's robust R&D capabilities and strategic initiatives suggest a positive trajectory. The Q&A section supports this with no significant concerns raised by analysts, reinforcing the positive sentiment.
YSG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
